Learn More
- BD ONCLARITY™ HPV Test for the FDA Approved HPV assay for extended genotyping
- Extended genotyping supports risk stratification and persistence monitoring to guide patient management
- Genotypes 16 and 18 account for 70% of invasive cancer worldwide, but their prevalence is declining as vaccination rates increase
- Genotypes 31, 33, 58 have a CIN3+ risk similar to genotype 18, but 51, 35, 39, 68, 56, 59, 66 have a much lower risk
Specifications
Type
HPV Test
Form
Ready-to-Use (RTU)
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.